髄膜炎菌ワクチンの世界市場規模：ワクチンタイプ別、エンドユーザー別、地域範囲別、予測

髄膜炎菌ワクチンの市場規模と予測

髄膜炎菌ワクチンの市場規模は、2024年に48億7,000万米ドルと評価され、2026年から2032年にかけてCAGR 5.54%で成長し、2032年には72億米ドルに達すると予測されています。

• 髄膜炎菌ワクチンは、髄膜炎や敗血症などの重篤な症状を引き起こす可能性のある髄膜炎菌による感染症を予防するために設計されています。
• 髄膜炎菌ワクチンは、少なくとも2年間は病気を予防する効果が85％～100％あります。
• 髄膜炎菌ワクチン（MenACWY）ワクチンは一般的に11～12歳の青少年に接種され、16～23歳の青少年には個人のリスクに応じてブースターが必要です。
• 髄膜炎菌ワクチンは一般的に、妊娠中の人を含む様々な集団で、副作用がないか継続的に監視しながら安全に使用できると考えられています。

髄膜炎菌ワクチンの世界市場力学

髄膜炎菌ワクチン市場を形成している主な市場力学は以下の通りです：

主な市場促進要因

• 髄膜炎菌疾患の発生率の増加：髄膜炎菌疾患の世界の報告件数の増加は、ワクチン市場の重要な促進要因です。例えば、2019年には全世界で約251万件の髄膜炎症例があり、うち128万件は5歳未満の小児でした。この憂慮すべき流行は、アウトブレイクを予防し、脆弱な集団を保護するための効果的なワクチン接種の重大な必要性を浮き彫りにしています。
• 政府の予防接種プログラム：例えば米国では、就学時や大学入学時にワクチン接種を義務付けているため、特にリスクの高い青少年の接種率が高くなっています。
• 公衆衛生への取り組み：世界保健機関（WHO）やワクチン同盟（Gavi）などの世界の保健機関は、ワクチン接種キャンペーンを支援し、低所得国でのワクチン配布に資金を提供しています。例えば、ナイジェリアでは最近、増加傾向にある髄膜炎菌感染症に対抗するため、Gaviの資金援助を受けて新しい5種混合髄膜炎菌ワクチン（Men5CV）を導入しました。
• 啓発・教育キャンペーン：医療従事者や一般市民の髄膜炎菌感染症の重症度に対する意識の高まりが、予防接種率の向上に寄与する青少年や若年成人に対するワクチン接種の重要性を強調するキャンペーンに対する需要を促進します。

主な市場課題：

• ワクチンの高コスト：髄膜炎菌ワクチンのコストは、特に中低所得国において、ワクチン接種を阻む大きな障壁となっています。血清群B型髄膜炎菌ワクチンなどのワクチンの価格は、新興国市場では1回当たり150ドルから250ドルであり、通常1回当たり50ドル以下の従来の小児用ワクチンよりも大幅に高くなっています。このような価格設定により、特にヘルスケア予算が限られている地域では、多くの人々がワクチン接種を受けることが難しくなっています。
• 限られた供給と製造能力：髄膜炎菌ワクチン市場は、製造業者の数が限られていることが特徴であり、供給の制約につながっています。WHOのデータによると、髄膜炎菌ワクチンの世界需要は約1億7,000万回分と予測されているのに対し、2019年の推定供給量は約2億回分でした。この格差は、様々な地域、特に有病率の高い地域のニーズを満たす上での課題となっています。
• ワクチン接種のためらいと誤った情報：ワクチンの安全性と有効性に関する誤った情報によって悪化しています。識字率が低く、ヘルスケアのインフラが十分でない地域では、このようなためらいがワクチン接種の大きな妨げとなります。
• ワクチン配布における物流の課題：遠隔地や十分なサービスを受けていない地域にワクチンを届けるには、ワクチン接種の妨げとなる物流の課題があります。多くの新興諸国では、医療インフラが不十分なため、コールドチェーン管理が必要なワクチンの保管や流通が複雑化し、ワクチン接種率の低下を招いています。

主な市場動向：

• 髄膜炎菌疾患の発生率の増加：CDCによると、細菌性髄膜炎は世界で毎年約120万件発生すると予測されています。この罹患率の増加は、効果的なワクチン接種戦略の緊急の必要性を強調しています。
• ワクチン接種プログラムの拡大世界各国政府は、国の予防接種スケジュールに髄膜炎菌ワクチンを含めるため、予防接種プログラムを拡大しています。この動向は、乳幼児、青少年、大学生、流行地への旅行者など、様々な層を対象としています。例えば、アイルランドなどの国では、髄膜炎患者の増加を受けて、最近10代の若者に対するMenACWYワクチンが承認されました。
• 一般市民の意識の高まり：髄膜炎菌感染症の深刻さについて、ヘルスケア専門家や一般市民の間で認識が高まっています。教育キャンペーンはワクチン接種の促進に役立っており、ワクチン需要の高まりにつながっています。調査によると、髄膜炎菌感染症に関連する致死率の可能性について保護者の認識が高まるにつれて、ワクチンの接種率は上昇する可能性が高いです。
• ワクチン開発における技術の進歩：ワクチン技術の革新が市場を牽引しています。複数の血清群（例：MenABCWY）を予防する多価ワクチンの開発により、接種率が向上し、接種スケジュールが簡素化されるため、ヘルスケアプロバイダーにとっても患者にとっても同様に接種が容易になると期待されています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 髄膜炎菌ワクチン市場：ワクチンタイプ別

• 4価ワクチン
• 2価ワクチン
• 血清群Aに対するワクチン

第5章 髄膜炎菌ワクチン市場：年齢層別

• 新生児と小児
• 思春期と若年成人
• 成人
• 高齢者

第6章 髄膜炎菌ワクチン市場：流通経路別

• 病院および診療所
• 小売薬局
• オンライン薬局

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• GlaxoSmithKline plc（U.K.）
• Pfizer Inc.（U.S.）
• Sanofi S.A.（France）
• Baxter International Inc.（U.S.）
• Serum Institute of India Pvt. Ltd.（India）
• Walvax Biotechnology Co., Ltd.（China）

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Meningococcal Vaccines Market Size And Forecast

Meningococcal Vaccines Market size was valued at USD 4.87 Billion in 2024 and is projected to reach USD 7.2 Billion by 2032, growing at a CAGR of 5.54% from 2026 to 2032.

• Meningococcal vaccines are designed to protect against infections caused by the bacteria Neisseria meningitidis, which can lead to serious conditions such as meningitis and sepsis.
• Meningococcal vaccines are between 85% and 100% effective in preventing disease for at least two years.
• The MenACWY vaccine is generally given to adolescents at ages 11-12, with a booster at age The MenB vaccine can be given to those aged 16-23 based on individual risk.
• Meningococcal vaccines are generally considered safe for use in various populations, including pregnant individuals, with ongoing monitoring for any adverse effects.

Global Meningococcal Vaccines Market Dynamics

The key market dynamics that are shaping the meningococcal vaccines market include:

Key Market Drivers:

• Increasing Incidence of Meningococcal Disease: The rising number of reported meningococcal disease cases globally is a significant driver for the vaccine market. For instance, in 2019, there were approximately 2.51 million cases of meningitis worldwide, with 1.28 million cases in children under five years old. This alarming prevalence highlights the critical need for effective vaccination to prevent outbreaks and protect vulnerable populations.
• Government Immunization Programs: Many governments have integrated meningococcal vaccines into their national immunization schedules, significantly boosting vaccine In the United States, for example, mandatory vaccination requirements for school and college entry ensure high coverage rates among adolescents, who are particularly at risk.
• Public Health Initiatives: Global health organizations like the World Health Organization (WHO) and Gavi, the Vaccine Alliance, support vaccination campaigns and provide funding for vaccine distribution in low-income countries. For example, Nigeria recently introduced a new 5-in-1 meningococcal vaccine (Men5CV) to combat rising cases, supported by Gavi's financial assistance.
• Awareness and Education Campaigns: Increased awareness among healthcare professionals and the general public about the severity of meningococcal disease drives demand for Campaigns emphasizing the importance of vaccination for adolescents and young adults contributing to higher immunization rates.

Key Market Challenges:

• High Cost of Vaccines: The cost of meningococcal vaccines is a significant barrier to access, particularly in low- and middle-income countries. Prices for vaccines, such as serogroup B meningococcal vaccines, can range from $150 to $250 per dose in developed markets, which is substantially higher than traditional childhood vaccines that typically cost under $50 per dose. This pricing makes it difficult for many populations to afford vaccination, especially where healthcare budgets are limited.
• Limited Supply and Manufacturing Capacity: The meningococcal vaccine market is characterized by a limited number of manufacturers, leading to supply constraints. According to WHO data, the global demand for meningococcal vaccines is projected at around 170 million doses, while the estimated supply was about 200 million doses in 2019. This disparity creates challenges in meeting the needs of various regions, particularly those with high disease prevalence.
• Vaccine Hesitancy and Misinformation: Vaccine hesitancy remains a critical challenge, exacerbated by misinformation regarding vaccine safety and effectiveness. In regions with lower literacy rates and poor healthcare infrastructure, this hesitancy can significantly impede vaccination Public reluctance to vaccinate can lead to lower coverage rates and increased vulnerability to outbreaks.
• Logistical Challenges in Vaccine Distribution: Delivering vaccines to remote or underserved areas poses logistical challenges that can hinder vaccination efforts. In many developing countries, inadequate health infrastructure complicates the storage and distribution of vaccines that require cold chain management, resulting in lower vaccination coverage.

Key Market Trends:

• Growing Incidence of Meningococcal Disease: The increasing prevalence of meningococcal disease is a significant driver of the vaccine According to the CDC, approximately 1.2 million cases of bacterial meningitis are projected to occur globally each year. This rising incidence underscores the urgent need for effective vaccination strategies.
• Expansion of Vaccination Programs: Governments worldwide are expanding their vaccination programs to include meningococcal vaccines in national immunization schedules. This trend targets various demographics, including infants, adolescents, college students, and travelers to endemic For instance, countries like Ireland have recently approved the MenACWY vaccine for teenagers due to rising meningitis cases.
• Increased Public Awareness: There is a growing awareness among healthcare professionals and the general public regarding the seriousness of meningococcal disease. Educational campaigns have been instrumental in promoting vaccination, leading to higher demand for vaccines. Research indicates that as parents become more aware of the potential fatality associated with meningococcal disease, vaccine uptake is likely to increase.
• Technological Advancements in Vaccine Development: Innovations in vaccine technology are driving the market forward. The development of multivalent vaccines that protect against multiple serogroups (e.g., MenABCWY) is expected to enhance coverage and simplify vaccination schedules, making it easier for healthcare providers and patients alike.

Global Meningococcal Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the meningococcal vaccine market:

North America:

• North America is expected to hold an estimated market share of 40.2% in 2024 and has been a leading region with revenues around USD 2.88 Billion in This dominance is attributed to high awareness levels regarding meningococcal diseases and effective vaccination strategies.
• The region benefits from a well-established healthcare system that supports widespread vaccination Strong healthcare infrastructure facilitates easy access to vaccines and ensures efficient distribution, contributing to higher immunization rates.
• Strong government initiatives, such as those from the Centers for Disease Control and Prevention (CDC), promote routine immunization against meningococcal The CDC recommends meningococcal vaccination for adolescents, which significantly boosts vaccine uptake.
• Major pharmaceutical companies in North America, such as GlaxoSmithKline (GSK) and Pfizer, invest heavily in R&D to develop new vaccines and improve existing formulations. This focus on innovation ensures a steady supply of effective vaccines that address emerging strains of Neisseria meningitidis.

Asia Pacific:

• The Asia Pacific region is projected to exhibit the highest compound annual growth rate (CAGR) of 14.7% from 2019 to 2026 in the meningococcal vaccines market, driven by increasing healthcare investments and growing awareness about meningococcal diseases.
• Many governments in the region are expanding their immunization programs to include meningococcal vaccines. For instance, the Indian government has initiated campaigns to vaccinate children against meningitis, recognizing the need to combat rising disease prevalence.
• Rising healthcare spending in developing countries enhances access to vaccines. According to various reports, countries in Asia Pacific are investing more in healthcare infrastructure and vaccine distribution, facilitating broader access to life-saving vaccinations.
• The presence of both domestic and international pharmaceutical companies focusing on vaccine development is increasing competition and innovation in the market. This includes partnerships aimed at improving production and distribution networks within Asia Pacific.

Global Meningococcal Vaccines Market: Segmentation Analysis

The Global Meningococcal Vaccines Market is Segmented on the basis of Product Type, End-User, And Geography.

Meningococcal Vaccines Market, By Product Type

• Quadrivalent Vaccines
• Bivalent Vaccines
• Serogroup A
• Serogroup B
• Serogroup X

Based on Product Type, The market is classified into Quadrivalent Vaccines, Bivalent Vaccines, Serogroup A, Serogroup B, and Serogroup X. Quadrivalent vaccines, which protect against four serogroups of Neisseria meningitidis (A, C, W, and Y), dominate the meningococcal vaccines market with an estimated share of approximately 60% in 2023. This high market share is attributed to their broad coverage and effectiveness in preventing meningococcal disease.

Meningococcal Vaccines Market, By End-User

• Children
• Pre-teens or Teens
• Adults

Based on End-User, the market is classified into Children, Pre-teens or Teens, and Adults. The pre-teens and teens segment accounted for approximately 57.9% of the market share in 2022. This high percentage reflects the increased susceptibility of this age group to meningococcal disease due to their developing immune systems and social interactions.

Meningococcal Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, The Global Meningococcal Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to hold an estimated market share of 40.2% in 2024 and has been a leading region with revenues of around USD 2.88 Billion in 2021. This dominance is attributed to high awareness levels regarding meningococcal diseases and effective vaccination strategies.

Key Players

The "Global Meningococcal Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as GlaxoSmithKline plc., Pfizer, Merck & Co., Serum Institute of India, Sanofi, Johnson & Johnson, AstraZeneca, Bavarian Nordic, BIO MED Private Limited, Chongqing Zhifei Biological Products Co., Bio-Manguinhos.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above- mentioned players globally.

• Meningococcal Vaccine Market Recent Developments
• In April 2024, GlaxoSmithKline plc announced the acceptance of their 5-in-1 meningococcal ABCWY vaccine (MenABCWY) for regulatory review by the U.S. FDA, which combines the protective elements of their existing vaccines to target five primary serogroups of Neisseria meningitidis (A, B, C, W, and Y).
• In July 2023, the Serum Institute of India launched MenFive(R), the first conjugate vaccine designed to protect against five predominant causes of meningococcal meningitis, specifically targeting serogroups A, C, W, Y, and X, and aimed at preventing outbreaks in the African meningitis belt.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Meningococcal Vaccine Market, By Type of Vaccine

• Vaccines classified as quadrivalents
• Vaccines classified as bivalents
• Vaccines against Serogroup A

5. Meningococcal Vaccine Market, By Age Range

• Newborns and Children
• Adolescents and Young Adults
• Adults
• Elderly

6. Meningococcal Vaccine Market, By Channel of Distribution

• Hospitals and clinics
• Retail Pharmacies
• Online pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GlaxoSmithKline plc (U.K.)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• Baxter International Inc. (U.S.)
• Serum Institute of India Pvt. Ltd. (India)
• Walvax Biotechnology Co., Ltd. (China)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References